CPRX
$5.74
Catalyst Pharm
($.02)
(.35%)
CPRX
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  $0.09
Revenue:  $32.46 Mil
Monday
Aug 9
5:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CPRX reports earnings?
Beat
Meet
Miss

Where is CPRX's stock price going from here?
Up
Flat
Down
Stock chart of CPRX
Analysts
Summary of analysts' recommendations for CPRX
Score
Grade
Pivots
Resistance
$5.97
$5.91
$5.82

$5.76

Support
$5.67
$5.61
$5.52
Tweet
Growth
Description
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3.
Peers
InterCeptBioMarin PharmaceuticalVertex PharmaceuticalsZoetisUltragenyx PharmaceuticalRegeneron PharmaceuticalsBristol-Myers SquibbPfizerEli LillyMerck & Co.